CME/CE Test

You are advising a large family practice about updated Advisory Committee on Immunization Practices (ACIP) recommendations regarding use of seasonal influenza vaccines in the United States. On the basis of the Morbidity and Mortality Weekly Report (MMWR) report by Grohskopf and colleagues, which one of the following statements about the updates from the 2021-22 recommendations is correct?

Composition of 2022-23 US influenza vaccines includes updates to influenza A(H3N2) component, but not to influenza B/Victoria lineage component

The approved age indication for the cell culture-based inactivated influenza vaccine, Flucelvax Quadrivalent (ccIIV4), was changed in October 2021 from ≥2 years to ≥6 months

Adults aged ≥65 years should receive only quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) or quadrivalent recombinant influenza vaccine (RIV4)

CME/CE Test

Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022–23 Influenza Season